Diagnosed with Cancer? Your two greatest challenges are understanding cancer and understanding possible side effects from chemo and radiation. Knowledge is Power!
Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- non-conventional therapies »
- I Don’t Buy It-“Algorithm Accurately Predicts Cognitive Decline in Parkinson’s Disease”
I Don’t Buy It-“Algorithm Accurately Predicts Cognitive Decline in Parkinson’s Disease”
Cognitive decline is one of the long-term outcomes of PD that has been largely unmanageable, and clinical trials are hampered by the highly varied rates of progression to cognitive clinical endpoints.
Predictions are a dime a dozen. I know because I was predicted to die in 3-5 years in 1994. Then I was predicted to be in “end-stage” of my cancer, multiple myeloma. A side effect of my high-dose, aggressivecalled chemo-brain has many similarities to cognitive decline. My cognitive decline has improved greatly over the years.
Even if you have been diagnosed with Parkinson’s Disease (PD) there are too many evidence-based therapies that have shown the ability to slow or even stop the progress of this awful disease.
If long-term outcomes are unmanageable and if rates of PD progression are highly varied then how can anyone predict anything in Parkinson’s Disease?
Consider evidence-based non-conventional therapies that healed my chemotherapy-induced cognitive dysfunction aka chemo brain. Therapies such as curcumin, frequent moderate exercise, lifestyle therapies such as saunas and more.
- “Cognitive decline is one of the long-term outcomes of PD that has been largely unmanageable and if
- “clinical trials are hampered by the highly varied rates of progression to cognitive clinical endpoints
I am a long-term cancer survivor and cancer coach. I have managed both my own cancer as well as my long-term and late stage collateral damage from conventional toxic therapies. I have managed my own cognitive decline aka chemobrain. I can’t say that my cognitive function is like it was when I was in my 20’s but then again, who can? I can say that supplementation, brain training and other lifestyle therapies have greatly improved my cognitive dysfunction.
Please scroll down the page and post a question or comment. I will reply to you ASAP.
Thank you,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Recommended Reading:
- Nutrition and Dementia
- Green Tea, Curcumin as Integrative, Synergistic Cancer Therapy
- The Ultimate Cancer Therapy – Eight Slices of the Magic Bullet
Algorithm Accurately Predicts Cognitive Decline in Parkinson’s Disease
“Prediction of cognitive decline within 10 years of onset of Parkinson’s disease (PD) is now possible through an analytic model developed by a multinational collaborative of investigators. The algorithm provides a set of clinical-genetic scores that accurately predict future dementia or disabling cognitive impairment…
Cognitive decline is one of the long-term outcomes of PD that has been largely unmanageable, and clinical trials are hampered by the highly varied rates of progression to cognitive clinical endpoints. The predictive algorithm designed by the International Genetics of Parkinson’s Disease Progression Consortium can facilitate effective risk stratification of patient populations to improve comparative results of clinical trials for disease-modifying therapies…
This predictive algorithm demonstrates good potential for use to address ongoing problems in clinical trial design for PD, as well as ultimate utility in general clinical settings. The consortium plans to develop the cognitive risk score calculator further to capture new predictive factors as they are discovered…”
References
Liu G, Locascio JJ, Corvol JC, et al. Prediction of cognition in Parkinson’s disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol. 2017;16:620-629.